Israel’s Teva and Sanofi announced promising Phase 2 trial results for duvakitug, designed to treat colitis and Crohn’s disease. In a 14-week phase 2b multi-national study, nearly 50% of patients achieved clinical remission compared with around 20% on a placebo. Teva’s shares rose 15%.

https://www.calcalistech.com/ctechnews/article/hymmfeyrjg